<DOC>
	<DOCNO>NCT02303574</DOCNO>
	<brief_summary>This phase I , randomise , single-blind placebo-controlled , 2-part study ass safety , tolerability , pharmacokinetics , pharmacodynamics food effect single multiple oral dos AZD7986 healthy volunteer</brief_summary>
	<brief_title>Single + Multiple Ascending Dose Food Effect Study AZD7986 Healthy Volunteers , PK , PD Safety Study</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>1 . Provision sign date write informed consent prior study specific procedure . 2 . Healthy male female subject age 18 50 year ( inclusive ) screen suitable vein cannulation repeat venepuncture . 3 . Females must nonchildbearing potential , confirm screen fulfil one follow criterion : Postmenopausal define amenorrhoea least 12 month follow cessation exogenous hormonal treatment follicle stimulate hormone ( FSH ) luteinising hormone ( LH ) level post menopausal range . Documentation irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . 4 . Male subject must non fertile , i.e. , surgically sterilise documentation azoospermia must practice effective contraceptive method prevent pregnancy . Effective contraceptive method : Sexual abstinence first administration IMP 3 month final administration IMP , line prefer usual lifestyle subject . Use condom plus spermicide agent addition partner use another acceptable method ( oral injectable hormonal contraceptive , contraceptive patch , intrauterine device , vaginal hormonal ring , vaginal diaphragm cervical cap ) first administration IMP 3 month final administration IMP . Subject 's sexual partner non childbearing potential , i.e. , post menopausal surgically sterilise ( e.g. , tubal ligation , hysterectomy medical history ) . 5 . Have body mass index ( BMI ) 18.0 30.0 kg/m2 inclusive weigh least 50 kg 100 kg inclusive screening . History clinically significant disease disorder , opinion Investigator , may either put subject risk participation study , influence result subject 's ability participate study . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . Any clinically important illness , medical/surgical procedure , trauma within 4 week first administration IMP . Subject increase risk infection : History and/or presence tuberculosis ( TB ) ; positive result interferon gamma release assay ( IGRA ) ( i.e. , QuantiFERON TBGold ) , subject resided region tuberculosis mycosis endemic 90 day screen , intend visit region duration study i.e . desert area , Eastern Europe , Central South America , Africa except Egypt , Russia , Asia , Indonesia Oral body temperature &gt; 37.7Â°C Day 1 , judge Investigator . Blood neutrophil count &lt; 1.7 x109/L ( Screening Day 1 morning sample ) . Is high riskgroup HIV infection within last 6 month ( i.e. , men unprotected sex men , woman sex without condom men sex men , people sex without condom person live travelled Africa , people inject drug , people sex without condom somebody injected drug , people catch another sexually transmit infection , people receive blood transfusion Africa , eastern Europe , country former Soviet Union , Asia central southern America ) . Other latent chronic infection ( e.g. , recurrent sinusitis , genital ocular herpes , urinary tract infection ) risk infection ( surgery , trauma , significant infection ) within 90 day screen , history skin abscess within 90 day screen . Clinically significant low respiratory tract infection resolve within 4 week prior screen , determine Investigator . Volunteers active malignancy neoplastic disease previous 5 year superficial basal cell carcinoma . Disease history suggest abnormal immune function . Volunteers receive live liveattenuated vaccine 4 week prior dose . Highsensitivity Creactive protein upper limit laboratory reference range screen Day 1 . Some subject lack functional dipeptidyl peptidase 1 ( DPP1 ) enzyme describe periodontitis palmoplantar hyperkeratosis : For Part 1a Part 1b : Subjects sign current gingivitis/periodontitis . Gingival evaluation ( inspection ) perform dental hygienist train study physician . For Part 2 : Subjects history recur gingivitis/periodontitis sign current gingivitis/periodontitis . Gingival evaluation perform dental hygienist train study physician . Evaluation bleed propensity due gingivitis perform use dental hygienist instrumentation . Exact measurement gum pocket need . Subjects history hyperkeratosis erythema palm sol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>AZD7986 , Safety , Tolerability , Pharmacokinetics , Pharmacodynamics , Food Effect , First-in-human , Single Ascending Dose , Multiple Ascending Dose , Healthy Subjects</keyword>
</DOC>